ASH2021 updated two novel bispecific BCMA-targeted CAR-T-cell products: the first targets two tumor-associated antigens (TAAs) (BCMA and CD24) (93), and another one constructs a synthetical CAR targeting the pan-TAAs, containing MHC class I polypeptide‐related sequence A/B (MICA/MICB), as the companion target of the classic target BCMA (94). The gene discussed is TNFRSF17; the disease is neoplasm.